Partner Article

Pharmaceutical firm takes on Europe

A NEWCASTLE based Pharmaceutical company will acquire three new manufacturing sites in Europe and double its workforce to 1400.

Having bought sites from UCB in Monheim, Zwickau in Germany and Pianezza in Italy, Aesica Pharmaceuticals will now look to capitilise on a lucrative European market.

Dr. Robert Hardy, Chief Executive, of the company, said: “The acquisition of the manufacturing sites is strategically crucial for our business as we extend and enhance our current offering and establish a presence in Europe.

“We hope to fully uttilise the expertise and knowledge across the current team at the new sites to facilitate our continued expansion and to achieve our vision of becoming the leading supplier of Active Pharmaceutical Ingredients and Formulated Products to the global pharmaceutical and biotechnology industries.”

Aesica is one of the UK’s fastest growing companies having more than trebled its turnover from £25M to approximately £90M over the last five years.

The firm is currently undergoing a period of significant and rapid expansion both in the UK and Europe, as well as across America - where it has recently opened new offices in San Diego and New York.

The European expansion follows Aesica’s acquisition of R5 Pharmaceuticals in June 2010 and will complement Aesica’s existing formulations capability, enabling it to “significantly consolidate” and extend its client portfolio.

This was posted in Bdaily's Members' News section by Ruth Mitchell .